Posted by Michael Wonder on 15 Feb 2024
Dermavant submits supplemental new drug application to FDA for Vtama (tapinarof) 1% cream for the treatment of atopic dermatitis in adults and children 2 years of age and older
14 February 2024 - sNDA is supported by positive data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials and interim results from the Phase 3 ADORING 3 open-label, long-term extension trial.
Dermavant Sciences today announced that it has submitted a supplemental new drug application to the US FDA for Vtama (tapinarof) 1% cream for the topical treatment of atopic dermatitis in adults and children 2 years of age and older.
